Oxurion NV — Major Shareholding Notification 2025

May 20, 2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Leuven, BELGIUM – May 20, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on May 16, 2025, from Atlas Special Opportunities II, LLC indicating that as of May 16, 2025, it held 1,535,806 shares of the then outstanding 6,156,035 shares, and therefore crossed under the threshold (25%) by virtue of the selling of voting securities.

Oxurion received a transparency notification on May 20, 2025, from Atlas Special Opportunities II, LLC indicating that as of May 20, 2025, it held 1,230,728 shares of the then outstanding 6,156,035 shares, and therefore crossed under the threshold (20%) by virtue of the selling of voting securities.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
	Name OXURION
ldentification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
B	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		16/05/2025 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
	25
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	6,156,035
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights	% of voting rights

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the secunties	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	1,724,103	1,535,806		24.95%
	1.535.806	0	24.95%	0.00%

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL				0	0.00%
The totals will be updated once you have clicked on P
TOTAL (A & B)				# of voting rights	% of voting rights
			CALCULATE	1,535,806	24.95%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

			(DD/MM/YYYY)
Holder	will cease to hold / will hold again	voting rights as of

13) Additional information

On 8 May 2025 (with settlement date on 12 May 2025), Atas Special Oportunities II LL sold 40,070 shares in Ourion its shareholding decreased to 1,684,033 stares (= 2.33%, Comment of Marcel can 1.0, 22, Ma 900 Mar 2010 Mar Baran Comments March Marcel 2007 Marc 2.00%
Commercial o 1.1 (2.00%) Collection Comments and Crime Comments of Marco Marc 2 denominator = 6,156,035).

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via th Send" button.

In addition, a signed copy in PDE format should also be transmitted.

ANNEX 2

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY		Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
	Name OXURION
ldentification number 0881-620-924
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name			Address (for legal entities)
	Atlas Special Opportunities II LLC		2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of votinq rights (only to be filled in if art. 7 of the Law applies)
	Name		Address (for legal entities)
B	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6		Part II
7) Date on which the threshold is crossed
			20/05/2025 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		20
			If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
		6,156,035
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification		After the transaction
	# of voting rights		# of voting rights	% of voting rights

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%
0

The totals will be updated once you have clicked on

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	1,230,728	19.99%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

	Atlas Special Opportunities II LLC is not a controlled entity.
12) In case of proxy voting for only one GM
Holder		will cease to hold / 0 will hold again	voting rights as of	(DD/MM/YYY)
13) Additional information
denominator = 6,156,035). denominator = 6,156,035). denominator = 6,156,035).	On 15 May 2025 with settenerit cate on 19 May 2025), Alas Special Operation NY, as a result of which is stareholding decreased of ,52 (372 stares (=24.7 %, On 15 May 2025 with settement cate on 19 May 2025), Mars II LC sold 23,124 shares in Oruin NV, as a result of which its stareholding decreased of 1,492,44 shares = 2.9%, On 16 May 2025 (with settenerit cate on 20 May 2025), Alass Special Cruino N, as a result of which is stranbolding decreased of 1,20,728 stares (= 19.9%,
	Done at New York
On		20/05/2025 (DD/MMYYYY)
	Name & capacity Patrick Vance, Proxyholder	Signature	Samed II Patrick Varce

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma_be. You can do this manually
OR if you have MS Outlook at your disposal via the "

In addition, a signed copy in PDE format should also be
transmitted.